Subcutaneous Injection

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

US FDA accepts NDA for exenatide once weekly for review

Published July 9, 2009, 5:48 am, PharmaBiz

Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the US Food and Drug Administration (FDA).

Discover News | Full Story


My Pharmiweb.com

Published July 9, 2009, 2:34 am, PharmiWeb

Tokyo and Osaka, Japan - July 8, 2009 – Wyeth K.K. (Wyeth) and Takeda Pharmaceutical Company Limited (Takeda) announced that on July 7, 2009 Wyeth had received approval from the Japanese Ministry of Health, Labour and Welfare to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to “ENBREL 25mg for S.C. Injection,” (etanercept) which Wyeth and Takeda co-promote.

Discover News | Full Story


Study shows Amgen drug helps prevent cancer-linked bone injury

Published July 7, 2009, 5:45 pm, Ventura County Star

(AP) — Shares of Amgen Inc. surged more than 13 percent in Tuesday after-hours trading, after the Thousand Oaks drugmaker said a late-stage clinical trial showed its experimental osteoporosis drug denosumab outperformed a rival product at preventing bone injuries in breast cancer patients. Amgen said patients treated with denosumab were free of skeletal injury — including fracture, bone ...

Discover News | Full Story


New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

Published July 7, 2009, 4:13 pm, redOrbit

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.

Discover News | Full Story


Amgen: Denosumab delays cancer-linked bone injury

Published July 7, 2009, 3:44 pm, INO News

(AP:THOUSAND OAKS, Calif.) Shares of Amgen Inc. surged more than 13 percent in Tuesday after-hours trading, after the drugmaker said a late-stage clinical trial showed its experimental osteoporosis drug denosumab outperformed a rival product at preventing bone injuries in breast cancer patients.

Discover News | Full Story


(AFX UK Focus) 2009-07-07 22:08 U.S. FDA advisory meetings through Aug 13

Published July 7, 2009, 2:39 pm, Interactive Investor

THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EDT/GMT. For more information on the FDA's Advisory Committee meetings, see: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm

Discover News | Full Story


New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

Published July 7, 2009, 1:06 pm, Business Wire via Yahoo! Finance

SAN DIEGO, INDIANAPOLIS & CAMBRIDGE, Mass.----Amylin Pharmaceuticals, Inc., , Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application for exenatide once weekly has been accepted for review by the U.S.

Discover News | Full Story


Zosano Pharma, Inc. Secures $30 Million in New Round of Financing

Published July 7, 2009, 1:00 pm, Business Wire via Yahoo! Finance

FREMONT, Calif.----Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that the company has closed a new round of financing in the amount of $30 million.

Discover News | Full Story


Schering-Plough announces phase II and III data for corifollitropin alfa

Published July 2, 2009, 9:48 pm, PharmaBiz

Schering-Plough Corp., announced results from the phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

Discover News | Full Story


The Online Information Source for the Medical Device Industry

Published July 2, 2009, 7:07 am, Medical Device Link

Convergent technologies are making new frontiers in medicine possible. Convergent technologies just may be the key to the future of medicine. Advances in nanotechnology, coatings, and molecular diagnostics have blurred the lines of devices and pharmaceuticals.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a